A commercially available biomarker of tubular epithelial cell damage (the product of tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 [TIMP-2*IGFB7] in urine) can be used to identify AKI prior to changes in serum creatinine levels or urine output. The gene discussed is TIMP2; the disease is acute kidney injury.